Unique ID issued by UMIN | UMIN000012544 |
---|---|
Receipt number | R000014680 |
Scientific Title | A randomized study comparing effects of donepezil and galantamine in Alzheimer disease :attentional function of clinical trial |
Date of disclosure of the study information | 2014/01/30 |
Last modified on | 2014/04/18 00:46:01 |
A randomized study comparing effects
of donepezil and galantamine in
Alzheimer disease :attentional function of clinical trial
A randomized study comparing effects
of donepezil and galantamine in
Alzheimer disease
A randomized study comparing effects
of donepezil and galantamine in
Alzheimer disease :attentional function of clinical trial
A randomized study comparing effects
of donepezil and galantamine in
Alzheimer disease
Japan |
Alzhimer disease
Psychiatry |
Others
NO
The aim of this study is to examine the treatment effect of both attention and motivation comparing effects donepezil to galantamine in both mild and moderate severity of Alzheimer disease
Efficacy
Exploratory
Pragmatic
Not applicable
Clinical assessment for spontaneity
1 Cognitive assessment
Mini-Mental State Examination (MMSE)
Clock drawing test
The Alzheimer Disease Assessment Scale cognitive subscale (ADAS-cog)
Frontal assessment battery (FAB)
2 Behavior assessment
Clinical assessment for spontaneity (CAS)
Neuropsychiatry Inventory Questionnaire (NPI-Q)
Quality of life-Alzheimer Disease (QOL-AD) Scale
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Active
YES
YES
Central registration
2
Treatment
Medicine |
The patients began treatment with donepezil 3mg once a daily. The total daily dose was increased by 5mg day.
The patients began treatment with galantamine 4mg twice daily. The total daily dose was increased by 16 mg day to a maximum of 24 mg day.
60 | years-old | <= |
95 | years-old | >= |
Male and Female
A diagnosis of probable AD according to the National Institute of Neurological and Communication Disorders and Stroke Alzheimer Disease and Related Disorders Association criteria, very mild to mild , moderate functional severity, reliable informed consent could be obtained from the patient and or his her relatives, the chief caregiver is the patients family ,the patients Mini Mental State Examination score was less than 11
either previous history or now taking other choline inhibitors (galantamine, rivastigmine) and memantine, taking antipsychotic or antidepressant medication
,there was a previous history of mental
llness or substance abuse,either an MRI or a CT scan had revealed focal brain lesions,routine blood tests (including evaluation of serum vitamin B12 and thyroid function) were abnormal findings
, the patient has pacemaker, other findings in terms with the aims of this study
26
1st name | |
Middle name | |
Last name | Shutaro Nakaaki |
Keio University School of Medicine
Department of Neuropsychiatry, Laboratory of Aging, Behavior and Cognition
35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582 Japan
03-3353-1211
hzi05510@nifty.com
1st name | |
Middle name | |
Last name | Shutaro Nakaaki |
Keio University School of Medicine
Department of Neuropsychiatry, Laboratory of Aging, Behavior and Cognition
35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582 Japan
03-3353-1211
hzi05510@nifty.com
Department of Neuropsychiatry, Keio University School of Medicine,
None
Self funding
none
none
NO
慶應義塾大学病院(東京都) Keio University School of Medicine (Tokyo)
2014 | Year | 01 | Month | 30 | Day |
Unpublished
Terminated
2012 | Year | 10 | Month | 22 | Day |
2014 | Year | 01 | Month | 31 | Day |
2015 | Year | 01 | Month | 31 | Day |
2015 | Year | 03 | Month | 29 | Day |
2015 | Year | 03 | Month | 30 | Day |
2015 | Year | 03 | Month | 30 | Day |
2013 | Year | 12 | Month | 10 | Day |
2014 | Year | 04 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014680